Cynvenio, ATGen See Launch of Cancer Diagnostic Study
Cynvenio Biosystems and Korea-based ATGen Global have announced the launch of a clinical study to evaluate Cynvenio’s ClearID test for the early detection of cancer in women.
The test — designed for women who have completed treatment for triple-negative breast cancer and show no radiographic signs of metastases — is based on its Cynvenio’s LiquidBiopsy technology along with ATGen’s NK Vue blood test.
The NK Vue test monitors the immune system for the presence of natural killer cells. It also can assess changes in patients with conditions in which innate NK cell activity has been reduced, including in certain cancers.
Enrollment in the trial will begin at Cynvenio’s lab in Westlake Village, Calif. It will be expanded to include academic medical centers in Chicago, New York and Pittsburgh in the first half of 2016. — Michael Cipriano